Please login to the form below

Not currently logged in
Email:
Password:

Cancer therapy deal for Teva and Sinclair

Teva Pharmaceutical and Sinclair IS Pharma are to team up to promote episil, a spray therapy for ongoing supportive cancer care

Teva Pharmaceutical and Sinclair IS Pharma are to team up to promote episil (benzydamine hydrochloride) an oral spray for the treatment of pain in patients undergoing chemotherapy and radiotherapy during cancer treatment.

The licence agreement will see Teva hold exclusive commercialisation rights for episil in Germany, Spain, Poland, Switzerland and the Czech Republic, while Sinclair IS is to retain an option to co-promote the drug in Germany and Spain where it has its own direct sales force.

Financial details of the deal were not disclosed.

Teva said it expects to launch episil in the fourth quarter of 2011.

Chris Spooner, CEO of Sinclair IS, commented that similar agreements were likely for the company in the future. He said: "This is the first in what we expect to be a number of marketing and co-marketing partnerships. episil is a cornerstone of our supportive oncology portfolio and we look forward to working with Teva as we drive sales of this product."

Sinclair IS was formed earlier this year following the merger of Sinclair and IS Pharma.

31st August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics